glp 1 glucose dependent insulin secretion GLP-1 promotes GLP-1: Actions on Beta-cell Mass

GLP-1 agonist shortage will last until end of 2024, government warns

Use it to log how you feel each day, spot patterns over time, and walk into your next doctor's appointment with a clear, organized summary no guessing, no trying to remember weeks of symptoms from memory

Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels

Makes skin healthier, smoother, and brighter

According to the National Institutes of Health (NIH), vitamin B12 hasnt been proven to cause any serious harm, even at high doses